Skip navigation
logo
(AFX UK Focus) 2009-11-18 21:29
BRIEF-Genentech and Biogen get FDA complete response for Rituxan in chronic lymphocytic leukemia
Article layout: raw

Nov 18 (Reuters) - Biogen Idec Inc:

  • GENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM THE FDA FOR
    Rituxan for chronic lymphocytic leukemia

  • SAYS IT AND GENENTECH WILL CONTINUE FINAL LABEL DISCUSSIONS WITH THE FDA

  • SAYS FDA HAS NOT REQUESTED ANY NEW DATA TO COMPLETE ITS REVIEW OF THESE
    applications

  • SAYS COMMITTED TO MAKING RITUXAN IN COMBINATION WITH FC AN FDA-APPROVED
    option for people with CLL

    ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here)

    COPYRIGHT

    Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

    		•
    Re-organisations, re-structurings, name changes, AGM, EGM
    General news
    Government regulatory actions
    Article layout: raw
    Jump back to site navigation